<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-octreotide.xml</id>
  <title>Recalls Watch: Octreotide</title>
  <link rel="self" href="https://recalls.watch/feed/substance-octreotide.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-05-13T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/98810/</id>
    <title>Teva Pharmaceuticals USA, Inc: Octreotide Acetate for Injectable Suspension</title>
    <link href="https://recalls.watch/recall/fda/98810/"/>
    <updated>2026-05-13T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98609/</id>
    <title>Teva Pharmaceuticals USA, Inc: Octreotide Acetate for Injectable Suspension and 2 more</title>
    <link href="https://recalls.watch/recall/fda/98609/"/>
    <updated>2026-04-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/n-mylan-institutional-llc-viatris-company-issues-voluntary-recall-one-lot-octreoti/</id>
    <title>Mylan Institutional LLC, a Viatris company: Mylan Institutional LLC: Octreotide Acetate Injection, 500 mcg/mL</title>
    <link href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-institutional-llc-viatris-company-issues-voluntary-recall-one-lot-octreotide-acetate-injection"/>
    <updated>2022-10-25T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Due to glass particulates</summary>
  </entry>
</feed>
